No Data
dian diagnostics group (300244.SZ): the monkeypox-related testing kit has obtained EU CE certification
Gelonghui November 6th | dian diagnostics group (300244.SZ) stated on the investor interaction platform that the company's monkeypox-related test kit has obtained EU CE certification, and the market is still being developed.
Express News | A share buyback overview: 38 companies disclose progress on buybacks
dian diagnostics group (300244.SZ): Buyback completed, cumulatively spent nearly 0.2 billion yuan to repurchase 13.88 million shares.
Gelonghui, October 31st, Dian Diagnostics Group (300244.SZ) announced that the company's share buyback implementation period is from March 8, 2024 to October 30, 2024. A total of 13.88 million shares of the company were repurchased through a designated securities account using centralized competitive trading, accounting for 2.22% of the company's current total share capital. The highest fill price was 18.91 yuan/share, the lowest fill price was 11.64 yuan/share, and the total fill amount was RMB 0.1995 billion (excluding transaction costs). With this, the company's share buyback scheme has been fully implemented.
Express News | dian diagnostics group signed an AI health management cooperation agreement with Huawei Cloud.
Dian Diagnostics Group Co.,Ltd. Just Missed EPS By 44%: Here's What Analysts Think Will Happen Next
dian diagnostics group (300244) Performance Review for the Third Quarter of 2024: Medical inspection business continues to be under pressure, lean management will benefit future growth.
Event: The company released the third quarter report for 2024, achieving revenue of 9.258 billion yuan from January to September 2024 (-10.05%), net income attributable to shareholders of 0.131 billion yuan (-75.35%), and non-net profit of 1.34 billion yuan.
No Data
No Data